UBS sets USD 53.00 target for Nektar Therapeutics stock

Published on 10/27/2026 at 21:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 10.13 million versus USD 10.43 million expected. Nektar Therapeutics stock costs EUR 34.15 on October 27, 2026, 2.77 percent above Tradegate close.

Analyst target and reporting date

UBS set a USD 53.00 target for Nektar Therapeutics on October 12, 2026.
Second-quarter revenue was USD 10.13 million versus USD 10.43 million expected.
Nektar Therapeutics stock costs EUR 34.15 at Lang & Schwarz on October 27, 2026 at 9:56 p.m. CEST, 2.77 percent above the Tradegate close of October 26, 2026.
Nektar Therapeutics is scheduled to report on November 5, 2026.

NKTR, US6402683063, Illustration mit AI erstellt.

Nektar Therapeutics (US6402683063) has a USD 53.00 price target from UBS after the bank initiated coverage with a Hold rating on October 12, 2026, according to Gekko. The target is 39.59 percent above the stock's USD 37.97 Nasdaq price on October 27, 2026. Nektar Therapeutics was trading at EUR 34.15 at Lang & Schwarz on October 27, 2026 at 9:56 p.m. CEST, up 2.77 percent versus the Tradegate close of October 26, 2026 at EUR 33.23.

Analyst view meets a low valuation base

UBS's target sits below several more bullish estimates. Gekko listed Piper Sandler at USD 192.00 on October 22, 2026, Leerink Partners at USD 130.00 and BTIG at USD 178.00. The same page showed 10 Buy, four Hold and zero Sell ratings among 14 firms, with a USD 133.08 consensus target.

Price remains near the yearly low

Nektar's Nasdaq price of USD 37.97 on October 27, 2026 stood 13.67 percent above its 52-week low of USD 33.40 and 65.17 percent below its 52-week high of USD 109.00. The company had a market capitalization of USD 1.1 billion and traded 567,772 shares during the latest Nasdaq session. The negative price-to-earnings ratio was minus 5.67.

Revenue and earnings date

Nektar reported second-quarter 2026 revenue of USD 10.13 million on August 13, 2026, below the USD 10.43 million consensus estimate, while adjusted earnings per share were a loss of USD 1.23 against an expected loss of USD 1.97, according to MarketBeat. The next earnings report is scheduled for November 5, 2026, after the market closes, according to Gekko.

Peer prices show a mixed biotech session

Nektar's Nasdaq stock was up 1.39 percent on October 27, 2026, compared with Iovance Biotherapeutics, which rose 5.81 percent to USD 14.58 with a USD 6.6 billion market capitalization. Immatics gained 1.54 percent to USD 7.26 and had a market capitalization of USD 1.1 billion. The comparison places Nektar's session move between the two biotechnology peers.

Target and price remain far apart

The UBS target gives Nektar a more measured valuation reference than the higher published targets, while the stock remains close to its 52-week low. For investors, the November 5 reporting date is the next scheduled event with potential to update revenue, cash and clinical-program expectations. Nektar Therapeutics stock was trading at EUR 34.15 at Lang & Schwarz on October 27, 2026 at 9:56 p.m. CEST, 2.77 percent above the Tradegate close of October 26, 2026 at EUR 33.23. The further course of trading is shown by the continuously updated real-time quote of Nektar Therapeutics stock.